Global and China Skateboard Chassis Industry Report 2024-2025: Market Fades in Overseas Markets, While it Begins to Come to the Fore in China
The 'Skateboard Chassis Industry Report Global and China, 2024-2025" report has been added to ResearchAndMarkets.com's offering.
Skateboard chassis research: already used in 8 production models, and larger-scale production expected beyond 2025
Global and China Skateboard Chassis Industry Report, 2024-2025 combs through and summarizes the status quo, installation, and suppliers' product layout of skateboard chassis, and also predicts its future development trends. This article will interpret the status quo of the industry from three perspectives: OEMs, suppliers, and the capital market.
Skateboard chassis fades in overseas markets, while it begins to come to the fore in China.
As giants Arrival and Canoo exit, skateboard chassis cools down in overseas markets.
In January 2024, Arrival, a prominent British skateboard chassis player, received a delisting notice from the NASDAQ Stock Market. In February 2024, the company filed for bankruptcy protection and eventually sold its assets to another startup, Canoo. Yet Canoo's car making dreams also came to an abrupt end this year. As the global pioneer of the model of making cars with skateboard chassis, Canoo launched pickups, sedans, and LDVs for freight, and successfully delivered products to renowned institutions such as National Aeronautics and Space Administration (NASA), the US Department of Defense, and the US Postal Service. It signed cooperation agreements with companies like Walmart. However, on January 17, 2025, Canoo announced that it had filed for bankruptcy protection and ceased operations immediately.
The exits of Arrival and Canoo, two skateboard chassis OEM giants, not only signify the end of their car making dreams but also indicate the development of skateboard chassis has a setback in the Western market.
Although skateboard chassis has cooled in overseas markets, several Chinese OEMs are still working to deploy skateboard chassis technology. They not only have had multiple production models equipped with skateboard chassis technology, but unveiled several new models featuring this technology in 2024.
Multiple Chinese OEMs deploy skateboard chassis technology, small-scale production for light commercial vehicles expected during 2025-2026.
According to incomplete statistics, about 14 models featuring skateboard chassis technology debuted in 2024, mainly light commercial vehicles planned for mass production during 2025-2026. In the passenger car segment, the model NIO S Liezhuang CIIC800V is currently planned to adopt skateboard chassis technology.
In China, 8 production models have already adopted skateboard chassis technology, of which most are light commercial vehicles such as logistics vehicle, light bus, and light truck, and a few are heavy trucks and passenger cars.
2023 to Early 2025: 7 suppliers secured 15 funding rounds, raising over RMB1.6 billion.
The train of financing events highlights the capital market's great attention to and support for the skateboard chassis segment. On one hand, the highly integrated and modular design of skateboard chassis can effectively shorten R&D cycles and reduce costs for automakers, aligning with the current trend towards intelligence and electrification in the automotive industry. On the other hand, its application potential in logistics, sanitation, public transport, and other fields is immense, making it a promising market. The influx of capital will further drive innovation and iteration in skateboard chassis technology, and accelerate commercialization of related companies, giving a big boost to the entire industry.
While skateboard chassis face challenges in overseas markets, it thrives in China. The reasons for this contrast include low penetration of new energy vehicles, insufficient policy support, and high supply chain costs overseas. The boom in China is credited to policy support, a mature supply chain, capital favor, and rapid technological iteration.
In addition to OEMs which vigorously make layout, the capital market has also shown strong enthusiasm, with high confidence in skateboard chassis:
Skateboard chassis solution suppliers target end scenarios, with multiple models in operation.
Skateboard chassis technology suppliers such as REE, PIX Moving, TEEMO Technology, ECAR Tech, and Seektop Automobile primarily apply their products to last-mile scenarios, including autonomous retail vehicles, autonomous cleaning robots, and autonomous logistics vehicles. Take PIX Moving and TEEMO Technology as examples:
In December 2024, PIX Moving, TIS, and the Hot Okinawa Research Institute formed a partnership. In this collaboration, TIS is responsible for introduction and planning, PIX Moving provides autonomous vehicles and technology, the Hot Okinawa Research Institute operates autonomous retail services, and Kanucha Resort (a resort in Nago City, Okinawa) provides application scenarios. PIX's autonomous retail vehicle Robo-Shop (eagle wing door version) has been put into operation in Okinawa, Japan, offering innovative unmanned mobile retail services to tourists. It can be intelligently dispatched according to tourist flow, automatically moving to crowded areas to sell snacks, beverages, and other goods, and supporting cashless payments.
TEEMO Technology's AutoBots-W7 mid-size intelligent skateboard chassis is designed for medium- and low-speed autonomous MPVs which are applicable to scenarios such as urban and campus delivery, unmanned logistics, factory logistics, and urban and rural sanitation. Its commercially produced skateboard chassis, AutoBots-W7, has been successfully installed on Zelos (Suzhou) Technology's urban autonomous distribution vehicles. Currently, Zelos has achieved large-scale deployment in over 20 provinces in China and more than 100 cities globally, covering scenarios like fresh food delivery, laundry delivery, cold chain distribution, and express delivery. Zelos finds broad application in express delivery, and partners with multiple express companies such as SF Express, China Post, YTO Express, ZTO Express, and STO Express.
Key Topics Covered:
Overview of Skateboard Chassis Industry
Skateboard Chassis Technology Layout of OEMs
Chinese and Foreign Skateboard Chassis Suppliers
Application Scenarios and Solutions for Skateboard Chassis
Development Trends of Skateboard Chassis
For more information about this report visit https://www.researchandmarkets.com/r/qm0590
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250421695553/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: CHINA ASIA PACIFIC
INDUSTRY KEYWORD: AUTOMOTIVE MANUFACTURING MANUFACTURING VEHICLE TECHNOLOGY GENERAL AUTOMOTIVE AUTOMOTIVE
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 04/21/2025 09:37 AM/DISC: 04/21/2025 09:36 AM
http://www.businesswire.com/news/home/20250421695553/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
JR-PLUS & Cinnamoroll Collaborative Campaign Starts!
NAGOYA, Japan & TOKYO--(BUSINESS WIRE)--During the period from Tuesday, August 19, to Monday, September 8, 2025, JR Central Retailing Plus Co., Ltd. stores will hold a Cinnamoroll Collaborative Campaign in conjunction with Cinnamoroll, the popular character from Sanrio Company, Ltd. In this campaign, stores will sell station lunchboxes (ekiben) and original goods only available through this collaboration, created with the concept of 'Cinnamoroll and his friends are helping out at station shops!' Two types of original 'KAWAII' illustrations only available during this campaign Uniform version for JR Central, which runs the Tokaido Shinkansen Uniform version as a chef, which is Cinnamoroll's 'dream' Sale of original collaborative goods Original goods with designs created specifically for this fair will be on sale. Ball chain mascot JR Central uniform ver.: 2,618 yen Ball chain mascot cafe uniform ver.: 2,618 yen Face coin purse: 1,540 yen Tote bag: 2,530 yen Drawstring bag 2P: 1,408 yen Three-pocket clear pouch: 2,178 yen Onigiri case (with carabiner): 2,178 yen Acrylic key chains (6 types): 770 yen each (4,620 yen for a box) Button badges (10 types): 550 yen each (5,500 yen for a box) Sale of original ekiben created in collaboration with Cinnamoroll Cinnamoroll Ekiben: 1,580 yen Other limited-offer collaborative package onigiri, sandwiches, and sweets will also be offered. Cinnamoroll Collaborative Campaign overview - Campaign dates: Tuesday, August 19, 2025 to Monday, September 8, 2025 - Campaign locations: Plusta, Bellmart, Grand Kiosk, Gift Kiosk, Precious Deli & Gift, etc. at Tokyo Station, Shinagawa Station, Shizuoka Station, Nagoya Station, Kyoto Station, Shin-Osaka Station, and others. See details here © 2025 Sanrio Co., Ltd. Approval No. L661918 *All prices include consumption tax. *All images are for illustrative purposes.
CNBC
27 minutes ago
- CNBC
Barclays second-quarter profit beats estimates as investment banking revenues swell
British bank Barclays on Tuesday beat profit expectations and announced a £1 billion ($1.33 billion) share buyback as market volatility boosted investment banking revenues. Pre-tax profit beat estimates at £2.5 billion ($3.34 billion) in the second quarter, compared with a mean LSEG forecast of £2.23 billion. Group revenues met analyst projections of £7.2 billion. Other highlights: Investors have been watching the performance of the lender's sharpened investment banking unit, which posted income of £3.3 billion in the three months to June, up 10% year-on-year. The division is the traditional backbone of Barclays' revenues and a target of cost reductions under CEO C.S. Venkatakrishnan unveiled in February 2024. It saw further changes in recent months, amid the hire of former Deutsche Numis exec Alex Ham as global chairman, a report of plans to cut more than 200 jobs and a report the bank is tapping consultancy McKinsey to identify further room for cost cutting. Adding to challenges, pending changes in U.S. capital leverage rules could unleash further competition stateside — where Barclays has had a significant presence since acquiring Lehman Brothers' investment banking and capital markets businesses — in the British lender's area of strength of debt markets. Domestically, Barclays faces a shifting British banking landscape, where Spanish titan Santander has doubled down on its U.K. presence with the early-July acquisition of British high street lender TSB from Sabadell, and investors are watching for any change in strategic tack from NatWest, which returned to private ownership at the end of May.
Business Wire
an hour ago
- Business Wire
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the completion of patient enrollment in the second cohort of its Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company's gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. Recruitment of the second cohort, composed of three patients aged between 6 and 31 months, was recently completed with the injection of the third patient. Patients in this second cohort were administered, unilaterally, a dose of d4.5 E 11 vg/vector/ear of SENS-501 which was higher than the dose in the 1 st cohort (1.5 E 11 vg/vector/ear). For all patients treated in the first and second cohorts, the surgical procedure was well tolerated: the intra-cochlear administration of the gene therapy product was uneventful. No serious adverse events and no serious side effects were reported. Early signs of hearing improvement have been observed in Patient 3, aged 11 months at the time of injection, three months after receiving the low dose. Nawal Ouzren, Chief Executive Officer of Sensorion, commented: "The completion of patient enrollment in the second cohort in Audiogene is an important milestone as it enables us to attest to the safety of the surgical approach, as no serious adverse events have been observed in all six patients injected, and of the good tolerability of SENS-501 to date. I look forward to advancing this innovative and unique program to its next steps, notably with the planned Data Monitoring Committee meeting, and to providing an update as soon as the data have sufficiently matured. On behalf of my colleagues, I would like to extend gratitude to the patients' families for their trust, as well as all the healthcare professionals involved in this clinical trial.' Professor Natalie Loundon, M.D., Director of the Center for Research in Pediatric Audiology, Pediatric Otolaryngologist and Head and Neck Surgeon, Necker Enfants Malades, AP-HP, in Paris, France, Principal Investigator of the Audiogene clinical study, added: 'I am thrilled we have successfully completed the patient enrollment of the second Cohort in Audiogene's Phase 1/2 gene therapy trial. The good tolerability of patients to SENS-501 so far and the preliminary positive data from the first cohort are very encouraging first steps for the continuation of this trial that has the potential to address a global significant unmet medical need. Once again, I would like to thank the patients' families for their trust.' Audiogene ( ID: NCT06370351) is the first gene therapy clinical trial addressing a unique homogeneous population of infants and toddlers (aged 6 to 31 months and naive of cochlear implants at the time of the injection, as per study protocol). Audiogene's clinical trial design has been intended to assess SENS-501 gene therapy product's safety and tolerability as well as its capacity not only to restore hearing but also to allow the infants and toddlers to acquire and develop normal speech. Moreover, Audiogene aims to evaluate the usability, the clinical and the technical performances of the injection system in development. About SENS-501 SENS-501 (OTOF-GT) is an innovative gene therapy program developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. This gene plays a key role in the transmission of auditory signals between the hair cells of the inner ear and the auditory nerve. When this gene is defective, affected individuals are born with severe to profound hearing loss. The aim of SENS-501 (OTOF-GT) is to restore hearing by introducing a functional copy of the OTOF gene directly into hair cells via viral vector technology (AAV). This therapy aims to restore the normal process of converting sound into electrical signals, enabling patients to regain their hearing ability. Currently in the clinical research phase, this gene therapy program represents significant hope for families affected by this rare form of genetic deafness. SENS-501 (OTOF-GT) embodies a commitment to scientific innovation in the field of hearing, with the potential to dramatically improve the quality of life of patients suffering from genetic deafness. This gene therapy for patients suffering from otoferlin deficiency has been developed in the framework of RHU AUDINNOVE, a consortium composed of Sensorion with the Necker Enfants Malades Hospital, the Institut Pasteur, and the Fondation pour l'Audition. The project is partially financed by the French National Research Agency, through the 'investing for the future' program (ref: ANR-18-RHUS-0007). The OTOF gene targeted by the Audiogene trial was discovered in 1999 at the Institut Pasteur, by Prof. Christine Petit's team (Institut reConnect, Institut de l'Audition, Pasteur Institute), who also unraveled the pathophysiology of the corresponding deafness (DFNB9). About the Audiogene Trial Audiogene aims to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in infants and toddlers aged 6 to 31 months at the time of gene therapy treatment. By targeting the first years of life, when brain plasticity is optimal, the chances of these young children with pre-linguistic hearing loss acquiring normal speech and language are maximized. The study comprises two cohorts of two doses followed by an expansion cohort at the selected dose. While safety will be the primary endpoint of the first part of the dose escalation study, auditory brainstem response (ABR) will be the primary efficacy endpoint of the second part of the expansion. Audiogene will also evaluate the clinical safety, performance and ease-of-use of the delivery system developed by Sensorion. About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
